Advanced search
Publication Cover
Infection and Drug Resistance Volume 11, 2018 - Issue
Submit an article Journal homepage
73
Views
18
CrossRef citations to date
0
Altmetric
Original Research

Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016

Hisashi Shoji1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain
,
Daniel A Vázquez-Sánchez1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain
,
Aida Gonzalez-Diaz1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain
,
Meritxell Cubero1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain
,
Fe Tubau1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain
,
Salud Santos2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain;3 Respiratory Medicine Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain
,
Dolores García-Somoza1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain
,
Josefina Liñares1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain
,
José Yuste2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain;4 Pneumococcal Reference Laboratory, Centro Nacional de Microbiología, ISCIII, Madrid, Spain
,
Sara Martí1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, SpainCorrespondence[email protected] [email protected]
&
Carmen Ardanuy1 Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain;2 CIBER de Enfermedades Respiratorias, ISCIII, Madrid, SpainCorrespondence[email protected] [email protected]
 show all
Pages 1387-1400 | Published online: 04 Sep 2018

References

  • Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750.
  • World Health Organization. Chronic respiratory diseases, chronic obstructive pulmonary disease (COPD). Geneva: World Health Organization; 2017. Available from: http://www.who.int/respiratory/copd/burden/en/. Accessed October 5, 2017.
  • Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
  • Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
  • Cimen P, Unlu M, Kirakli C, et al. Should patients with COPD be vaccinated? Respir Care. 2015;60(2):239–243.
  • Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed July 31, 2018.
  • Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190(7):1203–1211.
  • Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–1746.
  • Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043–2051.
  • Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48(1):57–64.
  • Ministerio de Sanidad, Servicios Sociales e Igualdad. 2015. Grupo de trabajo vacunación frente a neumococo en grupos de riesgo 2015 de la Ponencia de Programas y Registro de Vacunaciones. Utilización de la vacuna frente a neumococo en grupos de riesgo. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. [Working group record of vaccinations and vaccination against Pneumococcus in 2015 for the presentation of program risk groups. Use of the vaccine against Pneumococcus in risk groups. Health committee of the council inter-territorial national health system. Pneumococcal vaccination working group 2015]. Available from: http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Neumococo_Gruposriesgo.pdf. Accessed October 5, 2017. Spanish
  • Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333(8):474–480.
  • Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
  • Domenech A, Ardanuy C, Tercero A, García-Somoza D, Santos S, Liñares J. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods. J Antimicrob Chemother. 2014;69(4):932–939.
  • Domenech A, Ardanuy C, Calatayud L, et al. Serotypes and genotypes of Streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. J Antimicrob Chemother. 2011;66(3):487–493.
  • Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2012;163(5):1256–1276.
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement M100 – S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
  • Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard – Tenth Edition – M07 – A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
  • Càmara J, Marimón JM, Cercenado E, et al. Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain. PLoS One. 2017;12(4):e0175224.
  • Domenech A, Ardanuy C, Pallares R, et al. Some pneumococcal serotypes are more frequently associated with relapses of acute exacerbations in COPD patients. PLoS One. 2013;8(3):e59027.
  • Domenech A, Ardanuy C, Balsalobre L, et al. Pneumococci can persistently colonize adult patients with chronic respiratory disease. J Clin Microbiol. 2012;50(12):4047–4053.
  • McFetridge R, Meulen AS, Folkerth SD, et al. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2015;33(24):2793–2799.
  • Figueira-Gonçalves JM, Bethencourt-Martín N, Pérez-Méndez LI, et al. Impact of 13-valent pneumococcal conjugate polysaccharide vaccination in exacerbations rate of COPD patients with moderate to severe obstruction. Rev Esp Quimioter. 2017;30(4):269–275.
  • Lindstrand A, Galanis I, Darenberg J, et al. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden. Vaccine. 2016;34(38):4565–4571.
  • Hays C, Vermee Q, Agathine A, et al. Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children. Eur J Clin Microbiol Infect Dis. 2016;36(5):831–838.
  • Houseman C, Hughes GJ, Chapman KE, Wilson D, Gorton R. Increased invasive pneumococcal disease, North East England, UK. Emerg Infect Dis. 2017;23(1):122–126.
  • Sá-Leao R, Pinto F, Aguiar S, et al. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol. 2011;49(4):1369–1375.
  • Aguinagalde L, Corsini B, Domenech A, et al. Emergence of amoxicillin-resistant variants of Spain9V-ST156 pneumococci expressing serotype 11A correlates with their ability to evade the host immune response. PLoS One. 2015;10(9):0137565.
  • Rolo D, Fenoll A, Ardanuy C, et al. Trends of invasive serotype 6C pneumococci in Spain: emergence of a new lineage. J Antimicrob Chemother. 2011;66(8):1712–1718.
  • Janoir C, Cohen R, Levy C, et al. Clonal expansion of the macrolide resistant ST386 within pneumococcal serotype 6C in France. PLoS One. 2014;9(3):e90935.
  • Horácio AN, Silva-Costa C, Diamantino-Miranda J, et al. Population structure of Streptococcus pneumoniae causing invasive disease in adults in Portugal before PCV13 availability for adults: 2008-2011. PLoS One. 2016;11(5):e0153602.
  • Segal LN, Clemente JC, Wu BG, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax. 2017;72(1):13–22.
  • Kapatai G, Sheppard CL, Troxler LJ, et al. Pneumococcal 23B molecular subtype identified using whole genome sequencing. Genome Biol Evol. 2017;9(8):2122–2135.
  • Chewapreecha C, Harris SR, Croucher NJ, et al. Dense genomic sampling identifies highways of pneumococcal recombination. Nat Genet. 2014;46(3):305–309.

Reference

  • Domenech A, Ardanuy C, Tercero A, García-Somoza D, Santos S, Liñares J. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods. J Antimicrob Chemother. 2014;69(4):932–939.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.